Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Targeted testing for telogen effluvium patients can save healthcare costs.

Low levels of ferritin and vitamin B12 are common in women with telogen effluvium, but the link between nutrient deficiencies and the condition is not clear.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

This article reviews various factors contributing to telogen effluvium and examines potential treatments like Minoxidil, but reports no new clinical findings.

This study found that using urine tenofovir monitoring for PrEP adherence is well-accepted and may help overcome adherence barriers among participants at a U.S. urban clinical center.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This article discusses telogen effluvium in women, its causes, and typical diagnostic methods, but reports no new research findings on clinical outcomes or treatments.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This study found that resveratrol and fisetin promoted hair growth in mice by inducing telomerase reverse transcriptase expression, which activates hair follicle stem cells and transitions follicles from a resting to a growth phase.

This study found that women with telogen effluvium had significantly lower serum ferritin levels compared to healthy controls, suggesting an association between iron deficiency and this form of hair loss.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

In this study, telogen effluvium is characterized as a common condition in women involving sudden hair shedding due to hair follicles prematurely entering the telogen phase, with potential triggers including fever, childbirth, and stress.

Telogen effluvium is a common hair loss condition where many hairs enter the resting phase, often not noticeable until significant loss occurs, and treatment focuses on the underlying cause.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

This study reports a novel mutation in the TP63 gene associated with T and B cell lymphopenia in an EEC patient, suggesting that EEC diagnosis should include TREC assay and evaluation for immunodeficiency.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This review discusses the use of Tisseel for stabilizing particulate grafts and reports no new clinical results; the authors emphasize the need for further controlled trials.

This article presents a theory on the causes and development of telogen effluvium and reports no new clinical findings.